LAPACT: An open-label, multicenter phase II trial of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).
Philip Agop Philip(Wayne State University), Pascal Hammel(Hôpital Paul-Brousse), Christophe Borg(Centre Hospitalier Universitaire de Besançon), Wen Wee(Roswell Park Comprehensive Cancer Center), Jeanna Knoble(Columbus Community Clinical Oncology Program), Sheryl Koski(AstraZeneca (Australia)), Jill Lacy(Smilow Cancer Hospital), Giuseppe Tonini(Campus Bio Medico University Hospital), Tareq Al Baghdadi(IHA Hematology Oncology Consultants), L. Kayitalire, Javier Sastre(Hospital Clínico San Carlos), Fernando Rivera(Marqués de Valdecilla University Hospital), Alberto F. Sobrero(Ospedale Policlinico San Martino), Jimmy J. Hwang(University of California, San Francisco), Jack Li, Wasif M. Saif(Wayne State University), Scot Dowden, Dana B. Cardin(Vanderbilt University Medical Center), Venu Bathini(UMass Memorial Health Care), Eyal Meiri(Palm Beach Neurology)
Cited by 3
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k